Weight changes from GLP-1RA treatment in patients with PCSK1 gene mutations – two case reports

Two sisters with a loss-of-function PCSK1 mutation and class III obesity (BMI's 42 kg/m2 and 46 kg/m2) were treated with semaglutide and tirzepatide.

• Both sisters experienced significant weight loss of between 16% and 27% of their initial body weight.
• Neither sister had obesity-related diseases despite their severe obesity.
• The treatment involved medications that target appetite regulation.

Simplified